tbuckley/cabot-search huggingface dataset:
Management of Verterbral Compression Fractures (VCFs) in Multiple Myeloma (MM) Patients with Balloon Kyphoplasty
Authors: Charalampia Kyriakou, Anand Patel, Shivan Jassim, Adam Benton, Susanne Selvadurai, Syed Aftab, Amr Fahmy, Mathew David Sewell, Sean Molloy
Journal: Blood (2014)
Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) – A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT).
Authors: Mayur S Ramesh, Archana Thakur, Philip Pellett, Subhendu Das, Zaid S Al-Kadhimi, Lawrence G Lum
Journal: Blood (2009)
Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience.
Authors: D. H. Cauley, B. J. Atkinson, P. G. Corn, E. Jonasch, N. M. Tannir
Journal: Journal of Clinical Oncology (2011)

332 Background: Pneumonitis is a known adverse effect (AE) of mammalian target of rapamycin-inhibitors, with a literature reported incidence for everolimus ranging from 4 to 45%. The goal of this review was to characterize the incidence, timing, management, and outcomes related to everolimus-associated pneumonitis (EAP). Methods: Retrospective review of 86 mRCC patients (pts) with complete, evaluable records, given everolimus (E) between 4/2009 and 3/2010. We assessed baseline patient (pt) characteristics, previous therapies, time on E therapy, pt symptoms, physician management of AE, NCI-CTC pneumonitis grading, and survival outcomes. Radiologic CT indicated ground glass, inflammatory, and/or parenchymal opacities. Results: (See table.) EAP occurred in 28% of pts on E therapy, confirmed radiologically. 8% of EAP patients reported no symptoms. In EAP pts, 58% reported cough, 75% dyspnea and/or SOB, 17% fever, 71% fatigue. The median number of symptoms/patient was 3. 46% of pts received steroids (median 21 days (3-120)), 38% received antibiotics, 25% received pulmonary consultation, and 8% required oxygen. In pts who developed EAP, providers discontinued E in 75%, held and dose reduced E in 8%, and continued E in 17%. The median NCI-CTC pneumonitis grade was 2 (1-3); there were no treatment-related deaths. The median time to EAP onset was 67 days (8-442). There was no statistically significant difference in outcomes between EAP pts and non-EAP pts. Conclusions: EAP occurs often in mRCC pts treated with E. It is an important AE that can negatively affect pt symptoms, but did not adversely impact pt outcomes in our single-center experience. [Table: see text] [Table: see text]
Autologous Bone Marrow Mononuclear Cell (ABMMC) Transplantation in Type 1 and Type 2 Insulin Dependent Diabetes Mellitus (IDM).
Authors: Antonio A. Carrasco-Yalán, Roberto Fernandez-Vina, Jorge Castillo-Aguirre, Hugo Rios, L. More, N. Gomez, Samuel Chirino, Marcos Alvarez, M. Aranda, M. Arroyo, J. Rafael, A.N. Patel, Jorge Tuma-Mubarack
Journal: Blood (2007)
Immunohistochemical expression of cancer stem cell markers OCT3/4, NANOG, DPPA4, and CCND2 in testicular germ cell tumors.
Authors: Ravendra Ryan Moniz, Walter Henriques Costa, Victor Soares Fanni, Isabela Werneck Cunha, Rafael Malagoli Rocha, Gustavo Cardoso Guimaraes, Stenio C. Zequi
Journal: Journal of Clinical Oncology (2012)

333 Background: The purpose of this study was to examine the immunohistochemical expression of OCT3/4, CCND2, DPPA4 and NANOG in primary non-seminomatous germ cell testicular tumors that might be associated with different entities of germ cell tumors. OCT3/4, NANOG, DPPA4 and CCND2 have been identified as key regulators of pluripotency in mammalian embryonic and induced stem cells. Methods: Tissue samples of non seminoma testicular germ cell tumors including carcinoma in situ (CIS, n=10), seminoma component (n=5), embryonic carcinoma (n=20), mature teratoma (n= 7), immature teratoma (n=7), yolk sac tumor (n=5) and choriocarcinoma (n=3) were first analyzed by histological evaluation followed by selection of the appropriate tissue sections prepared from paraffin embedded testicular tissue blocks fixed with buffered formalin. To investigate immunohistochemical expression, of cancer stem cell markers samples tissues were analyzed under central pathological evaluation. Results: In CIS cells all markers were detected with a strong immunohistochemical expression suggesting that CIS cells maintain characteristics of embryonic stem cells. The invasive tumor samples, in comparison, showed a more heterogeneous expression pattern of OCT3/4, NANOG, DPPA4 and CCND2. There was an abundant expression in seminomas and embryonic carcinomas compared to a marked reduction expression in choriocarcinoma and teratomas. The expression of the markers was related to tumoral tissue differentiation. The seminomatous component and the embryonic carcinoma and undifferentiated tissues such as intratubular neoplasia presented elevated expressions. Specialized tissues such as teratoma and choriocarcinoma present low expression levels or absence of studied markers. The teratomatous subtypes do not express NANOG. The sub-type coriocarcinoma tumors do not express CCND2 and NANOG. Conclusions: The immunohistochemical expression of stem cell markers OCT3/4, NANOG, DPPA4 and CCND2 follow a specific pattern that is related to tumoral differentiation and consequent loss of pluripotency characteristics.
Perforator flap breast reconstruction in thin patients.
Authors: C. M. Chen, C. Ahn, J. Levine
Journal: Journal of Clinical Oncology (2011)

242 Background: Perforator flap breast reconstruction has strong appeal for many women seeking breast reconstruction, but the procedure requires adequate donor site tissue to produce realistic breasts. Thin women requesting perforator flaps are often advised that they lack sufficient donor site tissue for autologous tissue breast reconstruction, and that implants are their only option. We have expanded the reconstructive options for thin women who seek an alternative to implants with innovative new techniques. Methods: A retrospective review was done of 223 patients who underwent 293 consecutive perforator flap breast reconstructions from April 2007-May 2011. Preoperative imaging allowed visualization of the microvascular anatomy and subcutaneous tissue. Donor sites evaluated included the abdomen, medial thigh, buttocks, and back. Complications included flap loss, hematoma, seroma, takeback, and fat necrosis. No patients were turned away for perforator flap breast reconstruction due to insufficient donor site tissue. Results: Out of 293 perforator flap breast reconstructions, 45 perforator flap breast reconstructions (15.4%) were reported in 26 thin women with a BMI &lt; 23 (mean BMI 20.7, range BMI 18.2-22.7). Out of 45 perforator flap breast reconstructions in thin women, donor sites included 35 hemi-abdominal flaps (77.8%), 4 medial thigh flaps (8.9%), 7 buttock flaps (15.6%), and 2 back flaps (4.4%). Of the 35 hemi-abdominal flaps, 8 hemi-abdominal flaps were combined to create 4 stacked DIEP flaps (22.9%) while the remaining 27 hemi-abdominal flaps were regular DIEP flaps (77.1%). There was one seroma (2.2%) and one takeback for postoperative pain (2.2%); there were no flap losses. Conclusions: Even in thin women, perforator flap breast reconstruction is a safe, reliable, and consistent technique for recreating new breasts. While implant-based breast reconstruction may be acceptable to many women, there is a growing subgroup of patients who prefer autologous tissue breast reconstruction. By challenging common conceptions about the amount of donor site tissue required, we have been able to expand reconstructive options in thin women by using perforator flaps to construct natural, aesthetic breasts.
Outcome and treatment of 62 Patients Aged Over 75 Years with Low Grade Non Hodgkin Lymphoma
Authors: Anne Parcelier, Isabelle Leduc, Lavinia Merlusca, Gandhi Damaj, Amandine Charbonnier, Berengere Gruson, Saliha Sid-Idris, Jean Pierre Marolleau, Bruno Royer
Journal: Blood (2012)
Alcohol consumption: The single most important behavioral risk factor in breast cancer?
Authors: T. Lautenschlaeger, V. Dedousi-Huebner, A. Chakravarti
Journal: Journal of Clinical Oncology (2011)

176 Background: Breast cancer research has identified certain risk factors over the years, which influence a woman's chance of getting the disease. While factors such as personal history of breast abnormalities, age and the occurrence of breast cancer among first-degree relatives have been identified as estimation factors for breast cancer risk, other factors are less conclusive. Increasingly, obesity is being analyzed as a significant risk factor for many cancers and, after tobacco use, may be one of the most modifiable behavioral cancer risk factors. Interestingly when comparing the incidence rate of breast cancer to the obesity rate nationwide many states show a disparity in the two. It may be that other behavioral risk factors are of greater importance. Methods: The US States Mississippi and West Virginia display the highest rates of obesity (over 29.4% of their population display a BMI over 30.0) and the lowest rates in breast cancer incidence nationwide (under 113.9 and 113.5 people per 100.00. residents are diagnosed with cancer each year respectively). We set out to look at various behavioral risk factors to possibly detect an underlying pattern for breast cancer. Using selected metropolitan/micropolitan area risk trend data from the Behavioral Risk Factor Surveillance System from the CDC, we compared median percentages of the following risk factors: health status, exercise, diabetes, flu vaccination, current smoking, binge drinking and obesity. Results: Both states displayed higher percentages in all risk factors compared to the national average except for one in which they were below the national average: binge drinking. Rhode Island and Connecticut, the two states with the highest incidence rates in breast cancer, in turn displayed slightly higher rates of binge drinking compared to the national average. Conclusions: It appears that binge drinking might weigh more than other behavioral factors in terms of risk associated to breast cancer. Future research will need to analyze the interplay and patterns of the various risk factors as well as evaluate the association of mammographic density and alcohol drinking to further investigate the role of alcohol and binge drinking in the development of breast cancer.
A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.
Authors: Marcos de Lima, L. Padua, S. Giralt, C. Hosing, K. Komanduri, M. Qazilbash, E.J. Shpall, P. Thall, S. Qureshi, G. McCormick, W. Tong, U. Popat, A. Soriano, R. Champlin, G. Garcia-Manero
Journal: Blood (2007)
Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study.
Authors: N. Fleshner, M. S. Lucia, K. Melich, I. M. Nandy, L. Black, R. S. Rittmaster
Journal: Journal of Clinical Oncology (2011)

2 Background: The REDEEM (Reduction by Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer) study tested whether dutasteride controlled growth of existing low risk, localized prostate cancer (PCa) and hence reduced the need for aggressive therapy in men followed with active surveillance. Methods: 302 men, aged 48–82, with PSA &lt;11 ng/ml, and Gleason score ≤6 PCa (≤3 cores positive, &lt;50% of any core positive) were randomized to dutasteride or placebo for 3 years. Repeat 12-core biopsies were performed at 18 and 36 months, or for-cause at other times during the study. The primary endpoint was time to progression, defined as the earliest of either pathological progression (Gleason score &gt;6, ≥4 cores positive, or &gt;50% of any core positive) or therapeutic progression (radical prostatectomy, radiation therapy, or hormonal ablation). Results: 96% of subjects reached the primary endpoint or had a post-baseline biopsy. Dutasteride reduced time to PCa progression (relative risk reduction 38.9%, 95% CI: 12.4–57.4%, P=0.007). The table presents incidence of progression and Gleason score on final biopsy. 23% of men (N=31) in the placebo group and 36% of men (N=50) in the dutasteride group had no cancer detected on their final biopsy. PCa-related anxiety was reduced in the dutasteride arm compared to the placebo arm (P=0.036), based on the Memorial Anxiety Scale for PCa (MAX-PC). Drug-related adverse events were similar to those previously reported for dutasteride. Conclusions: In men followed with active surveillance, dutasteride delayed the time to PCa progression, increased the percent of men with no detectable PCa, and improved PCa-related anxiety. There was no evidence of increased Gleason score upgrading with dutasteride. Dutasteride may provide a useful adjunct to active surveillance for management of PCa. [Table: see text] [Table: see text]
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.
Authors: R. J. Motzer, T. E. Hutson, M. R. Olsen, G. R. Hudes, J. M. Burke, W. J. Edenfield, G. Wilding, B. Martell, S. Hariharan, R. A. Figlin
Journal: Journal of Clinical Oncology (2011)

LBA308 Background: In a randomized phase III trial, sunitinib 50 mg/d on Schedule 4/2 (4 wk on treatment [Tx], 2 wk off) showed superior progression-free survival (primary endpoint) to IFN-α (11 vs. 5 mo; p&lt;0.001) as first-line metastatic renal cell carcinoma (mRCC) therapy with a median overall survival (OS) of &gt;2 yr (Motzer 2009). Continuous dosing of sunitinib 37.5 mg has demonstrated antitumor activity with a manageable safety profile in first- and second-line mRCC (Barrios; Escudier, 2009). Methods: This randomized phase II trial compared sunitinib 50 mg/d on Schedule 4/2 (Arm A) vs. 37.5 mg continuous once-daily dosing (Arm B) in first-line mRCC. Eligible patients (pts) had clear cell locally recurrent or mRCC; measurable disease; and Karnofsky performance status ≥70%. Randomization (1:1) was stratified by MSKCC risk groups. Sunitinib was continued until progression, unacceptable toxicity, or up to 2 yr. The primary endpoint was time to tumor progression (TTP) by Kaplan-Meier estimate. Secondary endpoints included objective response rate (ORR), OS, and adverse events (AEs). Results: Between January 2007 and June 2008, 292 pts were randomized. As of October 2010, 289 pts had received sunitinib, and all pts were off therapy. Median age was 62 yr. 65% were male. By MSKCC criteria, 28%, 61%, and 11% were favorable, intermediate, and poor risk, respectively. Pts received a median 4 and 5 Tx cycles in Arms A and B, respectively; median relative dose intensity was 90.8% and 77.5%. Dose delays, reductions, and interruptions occurred in 30% vs. 13%, 36% vs. 43%, and 65% vs. 62%, respectively; 11% and 15% discontinued due to Tx-related AEs. Median TTP was 9.9 vs. 7.1 mo in Arms A and B, respectively (HR=0.773, 95.1% CI, 0.572, 1.044; p=0.090). ORR was 32.2% vs. 28.1% (p=0.444). Median OS was 23.1 vs. 23.5 mo (p=0.615). The most common Tx-related AEs were fatigue (both 62%), nausea (56% vs. 49%), and diarrhea (56% vs. 64%). Conclusions: In this randomized phase II mRCC trial, there was a trend toward inferior TTP with continuous dosing. ORR, OS, and AE profiles were similar for the approved sunitinib 50 mg/d dose on Schedule 4/2 vs. 37.5 mg continuous dosing. [Table: see text]
Significant interaction between testosterone recovery (TR) and biochemical progression-free survival (BPFS) in intermediate- and high-risk patients with prostate cancer treated with radiation therapy (RT) and androgen deprivation therapy (ADT).
Authors: D. Shasha, T. Nabhani, S. J. Rauth, R. Salant, L. B. Harrison
Journal: Journal of Clinical Oncology (2011)

202 Background: To examine the interaction testosterone-recovery-free survival (TRFS) and BPFS in patients with intermediate and high-risk prostate cancer treated with combined external beam radiation therapy (EBRT), prostate implant (PI), and ADT. Methods: We prospectively collected data between 1998 and 2010 from 1,564 patients with clinically localized prostate cancer treated by a single physician (DS). 294 patients with NCCN intermediate or high-risk prostate cancer were treated with EBRT, PI, and ADT. 60% of these patients had intermediate-risk disease. Initial prostate-specifc antigen (PSA), Gleason Score (GS), AJCC tumor stage (TStage), and RT parameters were recorded. PSA, and testosterone (T) were measured at each follow-up visit. BPFS was scored using the Phoenix definition. Testosterone recovery occurred when the serum T level rose above 150ng/ml. TR was dichotomized at 2 years. Survival was evaluated using Cox-regression analysis. Results: Median age was 66 yrs-old, intraquartile range (IQR) was 60-71. Median ADT duration (ADTD) was 1.31 years (IQR 0.25-2.35). Testosterone recovery (TR) was seen in 73% of patients. Median TRFS was 3.1 years (IQR 1.94-4.12). Median BPFS was 4.96 years (IQR 3.39-9.12). Overall BPFS was 90% in this patient population. Three patients experienced metastatic failure. There were no prostate cancer deaths. On univariate analysis ADTD (p=0.05), TRFS (p=0.04), GS (p=0.02), and PSA (p=0.05) were significantly associated with BPFS. On multivariable analysis TRFS (p=0.009), TStage (p=0.02), GS (p=0.02), and PSA (p=0.04) were significantly associated with BPFS. Conclusions: Prolonged testosterone suppression after combination EBRT/PI/ADT is strongly associated with improved BPFS. The physiological implications of this finding warrant further study. No significant financial relationships to disclose.
Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial.
Authors: J. W. Janni, P. G. M. Hepp, U. Andergassen, N. Harbeck, B. K. Rack, J. K. Neugebauer, K. Annecke, A. Wischnik, W. Simon, M. Rezai, T. N. Fehm, A. Schneeweiss, P. A. Fasching, B. Gerber, T. Zwingers, H. L. Sommer, K. Friese, M. Kiechle
Journal: Journal of Clinical Oncology (2011)

1020 Background: The prevalence of obesity increases throughout most industrialized countries. Epidemiological studies have shown not only an increase in breast cancer (BC) among obese women but also an adverse impact of obesity on BC survivors. This analysis focuses on the impact of obesity on high risk BC patients (pts) treated within the ADEBAR study protocol. Methods: The ADEBAR Trial compared 4 cycles of EC followed by 4 cycles of Doc vs. 8 cycles of FEC (120) in pts with primary BC (>=4LN). 1500 pts have been accrued from sep/01 through may/05. For this analysis data of 1361 pts has been analyzed about the impact of obesity on disease free survival. Therefore pts have been grouped to either underweight (BMI<18.5kg/m²), normal weight (BMI18.5−25kg/m²), overweight (25kg/m<BMI<=30kg/m²) or obese (BMI>30). Results: 13 pts (1.0%) were underweight, 557 pts (40.9%) were normal weight, 491 pts (36.1%) were overweight, 300 pts (22.0%) were obese at the time of study enrollment. After a follow up period of 60 months 87.5% of the underweight group, 70.4% of the normal weight group, 70.7% of the overweight group and 58.6% of the obese group were alive with no signs of recurrent disease (Chi-square=9.355; p< 0.0249). In univariate analysis also overall survival was significantly worse in the obese pts group (p = 0.014). There was no significant difference in survival between patients with normal weight and moderate overweight, respectively. In multivariate analysis, accounting for tumor size, lymph node status, histopathological grading, hormone receptor status, age, menopausal status and type of chemotherapy, not a BMI of greater than 25, but a BMI of greater than 30 was predictive for a significant higher risk for death. (hazard ratio 1.67 [1.14−2.45], p= .008. Additionally, a significant incremental effect for every BMI point could be shown, with an increased hazard ratio of 0.7 % for every kg per square meter. Conclusions: In conclusion, the results of this analysis confirm previous data on the detrimental impact of obesity on the survival of BC patients in this homogeneous group of individuals with high risk disease undergoing chemotherapy.
Quality and Safety in Health Care, Part XIX
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2016)

The integrated recovery pathway is a variant of the enhanced recovery pathway after surgery program, which saw a further decrease in complications and mean length of stay after a change in culture was instituted with more accountability of the staff to following the pathway. This was accomplished using a team-based comprehensive unit-based safety program. It has also been found that another variant of the enhanced recovery pathway after surgery program had a further improvement of patient outcomes after instituting a "preventive surgical site infection bundle."
Influenza Vaccination Coverage During Pregnancy — Selected Sites, United States, 2005–06 Through 2013–14 Influenza Vaccine Seasons
Authors: Stephen Kerr, Carla M. Van Bennekom, Allen A. Mitchell
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Seasonal influenza vaccine is recommended for all pregnant women because of their increased risk for influenza-associated complications. In addition, receipt of influenza vaccine by women during pregnancy has been shown to protect their infants for several months after birth (1). As part of its case-control surveillance study of medications and birth defects, the Birth Defects Study of the Slone Epidemiology Center at Boston University has recorded data on vaccinations received during pregnancy since the 2005-06 influenza vaccination season. Among the 5,318 mothers of infants without major structural birth defects (control newborns) in this population, seasonal influenza vaccination coverage was approximately 20% in the seasons preceding the 2009-10 pandemic H1N1 (pH1N1) influenza season. During the 2009-10 influenza vaccination season, influenza vaccination coverage among pregnant women increased to 33%, and has increased modestly since then, to 41% during the 2013-14 season. Among pregnant women who received influenza vaccine during the 2013-14 season, 80% reported receiving their vaccine in a traditional health care setting, (e.g., the office of their obstetrician or primary care physician or their prenatal clinic) and 20% received it in a work/school, pharmacy/supermarket, or government setting. Incorporating routine administration of seasonal influenza vaccination into the management of pregnant women by their health care providers might increase coverage with this important public health intervention.
The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia
Authors: Danielle C Croucher, Victor H Jimenez-Zepeda, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel
Journal: Blood (2011)
Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML)
Authors: Peter Herhaus, Stefan Habringer, Kathrin Philipp-Abbrederis, Tibor Vag, Carlos Gerngroß, Alexander Höllein, Torben Altmann, Catharina Müller-Thomas, Julia Slotta-Huspenina, Christian Peschel, Markus Schwaiger, Hans-Jürgen Wester, Mareike Verbeek, Karsten Spiekermann, Katharina Götze, Ulrich Keller
Journal: Blood (2015)